Acrivon Therapeutics (NASDAQ:ACRV) Upgraded at Wall Street Zen

Posted by Geri Gentry on Oct 8th, 2026

Wall Street Zen upgraded shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) from a sell rating to a hold rating in a research note published on Monday morning,Wall Street Zen reports.

Separately, Weiss Ratings cut Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $13.50.

Read Our Latest Report on Acrivon Therapeutics

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV opened at $1.88 on Monday. The stock has a market cap of $80.56 million, a price-to-earnings ratio of -1.00 and a beta of 1.91. Acrivon Therapeutics has a 12 month low of $1.27 and a 12 month high of $3.56. The stock’s 50 day moving average price is $1.96 and its 200 day moving average price is $1.78.

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. On average, sell-side analysts expect that Acrivon Therapeutics will post -1.76 EPS for the current year.

Insider Transactions at Acrivon Therapeutics

In other Acrivon Therapeutics news, CEO Peter Blume-Jensen sold 14,036 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total value of $31,019.56. Following the transaction, the chief executive officer owned 2,230,052 shares of the company’s stock, valued at approximately $4,928,414.92. This represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 18,547 shares of company stock valued at $39,435 in the last quarter. Insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

A hedge fund recently raised its position in Acrivon Therapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) by 19.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 758,440 shares of the company’s stock after purchasing an additional 124,271 shares during the period. Renaissance Technologies LLC owned approximately 1.77% of Acrivon Therapeutics worth $1,054,000 at the end of the most recent quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its Acrivon Predictive Precision Oncology (AP3) platform to identify tumor characteristics that may predict a patient’s response to specific targeted therapies.

Acrivon’s lead program is ACR-368, an orally administered small-molecule inhibitor designed to target the checkpoint kinase 1 (CHK1) and WEE1 proteins, which help regulate tumor-cell replication and DNA damage responses.